Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

Key Takeaway: CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the Evercore ISI 2nd Annual HealthCON

Full Press Release Details

CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 8:20 a.m. ET in Boston, MA.
A live webcast of Intellia’s presentation will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcast, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for approximately 14 days following each conference.
About Intellia Therapeutics
Jennifer Mound Smoter
Senior Vice President
External Affairs & Communications
Last updated: Nov 26, 2019